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ABSTRACT 
 
Background: Disability-adjusted life years (DALYs) are an indicator of mortality, 
morbidity and disability. We calculated DALYs for cancer in middle-aged and older 
adults participating in the CHANCES consortium (Consortium on Health and Ageing 
Network of Cohorts in Europe and the United States). 
Methods: A total of 90,199 participants from five European cohorts with 10,455 
incident cancers and 4,399 deaths were included in this study. DALYs were 
calculated as the sum of the years of life lost due to premature mortality (YLLs) and 
the years lost due to disability (YLDs). Population attributable fractions (PAFs) were 
also estimated for five cancer risk factors, i.e. smoking, adiposity, physical inactivity, 
alcohol intake, and type II diabetes. 
Results: After a median follow-up of 12 years, the total number of DALYs lost from 
cancer was 34,474 (382 per 1,000 individuals) with a similar distribution by sex. Lung 
cancer was responsible for the largest number of lost DALYs (22.9%), followed by 
colorectal (15.3%), prostate (10.2%), and breast cancer (8.7%).  Mortality (81.6% of 
DALYs) predominated over disability. Ever cigarette smoking was the risk factor 
responsible for the greatest total cancer burden (24.0%; 95% CI=22.2%-26.0%) 
followed by physical inactivity (4.9%; 95% CI=0.8%-8.1%) and adiposity (1.8%; 
95% CI=0.2%-2.8%). 
Conclusions: DALYs lost from cancer were substantial in this large European sample 
of middle-aged and older adults. Even if the burden of disease due to cancer is 
predominantly caused by mortality, some cancers have sizeable consequences for 
disability. Smoking remained the predominant risk factor for total cancer burden.  
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INTRODUCTION 
 Mortality and morbidity are the most widely used indicators to evaluate 
population health, and cancer is one of the leading causes of morbidity and mortality 
worldwide (1). However, a growing body of literature proposes the use of summary 
measures of population health, such as the disability-adjusted life years (DALYs), 
which reflects both healthy life years lost due to premature death as well as years of 
life spent with disability from a disease (2). DALYs were introduced by the World 
Bank in 1993, and have been used since then by the World Health Organization to 
publish regular updates on the burden of diseases and injuries worldwide. The global 
average burden of all diseases in 2012 was 388 DALYs per 1,000 individuals, of 
which about 73% was due to premature death and 27% due to non-fatal health 
outcomes (3). In high income countries, cancer contributed to 17% of the total 
DALYs lost, with lung, colorectal, and breast cancer being the three leading cancer 
causes of lost healthy life years. 
The increase in survival rates for many cancer types over recent decades 
warrants the study of not only cancer incidence and mortality but also of the non-fatal 
consequences of cancer, such as the decrease in quality of life and the relative 
disability of cancer patients. However, there have been few attempts to estimate the 
burden of cancer using data from cohort studies. Therefore, the aims of the current 
study are to calculate DALYs for cancer, overall and by cancer site, in a large and 
diverse population of middle-aged and elderly Europeans, and to estimate population 
attributable fractions for selected cancer risk factors (smoking, adiposity, alcohol, 
physical inactivity, and type II diabetes) based on the calculated DALYs. 
 
METHODS 
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Study population 
CHANCES (Consortium on Health and Ageing Network of Cohorts in Europe and the 
United States) is a large collaborative project established in 2010 to investigate 
determinants of health and disease of an aging population (4). Five CHANCES 
cohorts in Europe (EPIC-Elderly, ESTHER, NSHDS, MORGAM, PRIME BELFAST 
and Tromsø Study) have provided data for the current analysis. The total study 
population comprised 90,199 participants after excluding those with prevalent cancer 
at recruitment. Detailed information about this consortium, its component studies and 
their cancer assessment methods can be found in the Supplementary Methods and in 
prior publications (4-10). All participants provided written informed consent, and 
approval of the study was obtained from the ethics committees at the participating 
institutions. 
 
Statistical analysis 
Calculation of Disability-adjusted Life Years 
To calculate DALYs we used the first incident malignant cancer cases (n=10,455) 
from the five participating cohorts. We added the years of life lost due to premature 
mortality (YLL) to the years lost due to disability (YLD) following a published 
formula and the methodological principles employed in the original Global Burden of 
Disease study (2). We computed the YLL by multiplying the number of deaths due to 
cancer by the number of years of expected remaining life at the respective age of 
death according to the West life table (2). The YLD is computed by multiplying the 
number of first incident cancers by the duration of cancer and a disability weight that 
reflects the severity of the phases in the natural history of each cancer. We calculated 
DALYs overall and separately for each cancer site by sex, age group (five-year 
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groups) and participating cohort. Age standardized DALYs lost per cancer case were 
also calculated using the direct method to allow for comparison between sexes and 
cohorts.  
 The duration of cancer in the YLD calculation was derived from data for each 
of the participating cohorts, and from external information used in prior publications 
(2, 11). Duration of disease was defined as the time interval from the cancer diagnosis 
until death for those who died from cancer. For cancer patients who died from other 
causes or that were still alive at the administrative end of the study, duration of 
disease was defined as the minimum of either five years or the time interval from 
cancer diagnosis until death from other causes or the administrative end of the study, 
respectively. Disability weights and their 95% confidence intervals (CIs) were derived 
from prior national burden of disease studies with the person trade-off method using a 
scale of 0 to 1 (2, 11, 12), where 1 means death and 0 means absolute health 
(Supplementary Table 1). DALYs were also calculated in sensitivity analyses using 
the lower and the upper estimates of the 95% CIs for the disability weights in a best 
and worst case scenario, respectively. In order to apply these disability weights, 
duration of cancer was divided in four phases (diagnosis and primary therapy, after 
primary therapy [follow-up], pre-terminal and terminal) (11-13). Patients who died 
from cancer underwent a period of disability in all aforementioned disease phases, 
where the terminal phase was uniformly set to one month and the pre-terminal phase 
set to three months. The diagnosis and primary therapy phase was set to 12 months or 
less depending on the total duration of the disease (Supplementary Table 2). Cancer 
patients that were still alive at the administrative end of the study or those who died 
from a cause other than cancer underwent a period of disability only in the first two 
disease phases, where the diagnosis and primary therapy phase was set to 12 months 
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or less depending on the total duration of the disease (Supplementary Table 2). The 
calculation of DALYs traditionally includes two social value functions, an age-
weighting function and a 3% discount rate (2), and we performed sensitivity analyses 
to assess the impact of omitting these functions. 
 
Calculation of population attributable fractions 
We calculated population attributable fractions (PAFs) for five major cancer risk 
factors namely smoking, adiposity, physical inactivity, alcohol intake, and type II 
diabetes. We used the generalized Greenland formula that allows adjustment for 
confounders and terms for more than two levels of exposure (14). Cox proportional 
hazard models were performed to calculate hazard ratios and 95% CIs by cohort and 
also after pooling the data from all cohorts together for the association between the 
afore-mentioned risk factors and cancer incidence and mortality by cancer site using 
age as the underlying time scale. Proportionality of hazards was verified using the 
Schoenfeld residuals. The risk estimates in the pooled analysis were compared to 
summary random effect meta-analysis estimates calculated using the DerSimonian 
and Laird method (15). The risk estimates from the pooled analysis for cancer 
incidence were used in the calculation of PAFs for YLDs, whereas the estimates for 
cancer mortality were used in the calculation of PAFs for YLLs. Models were 
stratified for age, sex, and mutually adjusted for the latter five risk factors. To further 
explore residual confounding due to smoking, models were also run among never 
smokers. Missing values for the five risk factors were assigned to separate categories, 
and missing indicators were used in the statistical models. Analyses that excluded 
participants with missing values for any of these variables gave very similar results 
and are not presented here. Information on the assessment of the five risk factors is 
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provided in the Supplementary Methods. All statistical analyses were performed 
using STATA version 12 (College Station, TX), and the PAFs were calculated using 
the built-in routine punafcc. 
 
RESULTS 
 Overall, 90,199 participants were followed-up for a median of 12 years, of 
whom 10,455 individuals (1,115 per 100,000 person-years) developed a new cancer 
and 4,399 (519 per 100,000 person-years) died from cancer (Table 1). The mean age 
at recruitment ranged from 54.3 years in the PRIME study to 63.8 years in EPIC-
Elderly, and most cohorts had a similar proportion of men and women except for 
PRIME and EPIC-Elderly. Mean BMI levels ranged from 26.1 to 27.7 kg/m2 with the 
highest mean BMI observed in the ESTHER and EPIC-Elderly cohorts.  
 Table 2 shows the number and age-standardized incidence rates of cancer 
cases and deaths by cancer site and cohort. Prostate cancer was the most frequently 
diagnosed cancer in most cohorts with 2,201 overall cases (552 per 100,000 person-
years in men), followed by colorectal, breast, and lung cancer, whereas lung cancer 
was the leading cause of cancer death in all cohorts with 1,062 total events (120 and 
203 per 100,000 person-years overall and only in men, respectively) followed by 
colorectal, prostate, and pancreatic cancer.  
 The number of YLLs, YLDs and DALYs are shown in Figure 1 and in 
Supplementary Table 3 for the 21 cancer sites with at least 50 overall cases in the 
CHANCES. Supplementary Table 4 shows this in more detail by cohort, sex, and 
five-year age categories. The total number of DALYs lost from these 21 cancers was 
34,474 (382 per 1,000 individuals), and there were a total of 28,114 YLLs and 6,360 
YLDs lost. YLLs represented 81.6% of total DALYs. Lung cancer was responsible 
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for the largest number of DALYs lost (22.9%), followed by colorectal (15.3%), 
prostate (10.2%), and breast cancer (8.7%). When we excluded the time discounting 
and the age weighting from the DALYs in a sensitivity analysis, the ranking of 
cancers based on YLLs, YLDs and DALYs remained the same (Supplementary 
Table 5). Similar results were also observed when we used the lower and the upper 
estimates of the 95% CIs for the disability weights (Supplementary Table 6). 
 After analyzing the two components of DALYs by cancer site, lung cancer 
accounted for the highest number of YLLs (25.6%), whereas breast cancer was 
responsible for most YLDs (22.4%) (Figure 1 and Supplementary Table 3). For 17 
cancers the YLLs were much larger than the YLDs with a YLL to YLD ratio larger 
than two. Pancreatic and liver cancers registered an extreme ratio of more than 20, as 
they have the worst documented survival rates, and had the smallest median duration 
of cancer and among the largest median disability weights in our study 
(Supplementary Table 3). Breast and endometrial cancer had the smallest YLL to 
YLD ratios of 1.1 and 1.4, respectively. 
 The overall burden of cancer was similar by sex, but large differences were 
observed for certain cancer sites (Figure 2 and Supplementary Table 4). Neoplasms 
of lung, bladder, stomach, head and neck, esophagus, melanoma, non-Hodgkin's 
lymphoma, leukemia and multiple myeloma predominantly affected men. In contrast, 
thyroid, brain and gallbladder cancer were responsible for a greater burden of disease 
in women. However, the age-standardized DALYs lost per cancer case were slightly 
larger in women (Supplementary Table 4). In terms of the age distribution, patients 
aged 65 to 69 years registered for the highest number of absolute DALYs lost due to 
cancer, but the age-standardized DALYs lost per cancer case were larger in the 
younger age groups (Supplementary Table 4).  
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 We also estimated the percent of total DALYs lost due to cancer that is 
attributable to five major risk factors to evaluate the potential for future health gains 
by reducing population exposure to these factors. Supplementary Table 7 shows the 
hazard ratios and 95% CIs for the association of the risk factors with cancer incidence 
and mortality by cancer site, cohort, and overall after pooling and also meta-analyzing 
the data from the five participating cohorts. The hazard ratios from the pooled 
analyses and the meta-analyses were generally in high agreement with very few 
exceptions. The observed risk estimates in the pooled analyses were also generally 
concordant in the direction of the effect with the literature evidence from published 
meta-analyses (Supplementary Table 7). Table 3 depicts the PAFs for risk factors 
and cancer sites that showed statistical significance in the pooled analysis. Negative 
values represent protective associations based on the presented risk factor modeling. 
Current and former cigarette smoking combined was the risk factor responsible for the 
greatest cancer burden. Ever smoking could explain 24.0% (95% CI=22.2%-26.0%) 
of total cancer burden followed by physical inactivity (4.9%; 95% CI=0.8%-8.1%) 
and adiposity (1.8%; 95% CI=0.2%-2.8%). A larger proportion of total cancer burden 
due to smoking was observed in men (30.5%; 95% CI=27.5%-34.3%) compared to 
women (18.6%; 95% CI=16.6%-20.4%). Forty-eight percent (95% CI=46.4%-48.8%) 
of the lung cancer burden was due to ever smoking, followed by 39.3% (95% 
CI=34.3%-45.1%) for bladder cancer and 34.2% (95% CI=22.4%-43.1%) for 
esophageal cancer. Overweight and obesity caused an estimated 28.5% (95% 
CI=12.7%-41.0%) of the burden for endometrial cancer. Abstaining from vigorous 
physical activity led to 36.0% (95% CI=20.1%-49.0%) of burden from liver cancer.  
 
DISCUSSION 
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 This study provides an estimation of the burden of disease due to cancer in 
five large prospective European cohorts of the CHANCES consortium. The burden of 
disease due to cancer was 34,474 DALYs, which translates to an average loss of 
38.2% of the healthy life expectancy among the individuals in this study. Mortality 
predominated over disability, but breast and endometrial cancer had sizeable 
consequences also for disability. Lung cancer was responsible for the largest number 
of lost DALYs followed by colorectal, prostate and breast cancer. Smoking remained 
the predominant risk factor for total cancer burden. 
 The large figure of 382 DALYs lost due to cancer per 1,000 individuals in the 
current study suggests that there are still considerable opportunities for improving the 
health burden related to malignancies in Europe. National policies should be further 
strengthened to reduce cancer incidence and mortality and to prevent disability. This 
figure is not consistent with that of 54 DALYs per 1,000 individuals calculated by the 
World Health Organization for Europe in 2012 or by similar estimates from other 
national burden of disease studies (3, 16, 17). That is because the current study 
consisted of middle-aged and older adults and calculated DALYs based on only 
incident cancer cases, and thus it cannot be representative for the burden of disease 
due to prevalent and incident cancer across all ages like in previous publications. The 
use of real-life follow-up in the current study enables the prospective calculation of 
observed information for cancer incidence, mortality, risk factor and confounding 
variables compared to aggregate modeled data used in prior publications.  
 The larger proportion of DALYs lost in the current study was sequentially due 
to lung, colorectal, prostate and breast cancers. This ranking of the top cancers was 
concurrent to the WHO Global Burden of Disease estimates for cancer in Europe in 
2012 and other national burden of disease studies (3, 13, 17). In addition, the ranking 
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of cancers based on DALYs was similar to the ranking based on mortality, which is in 
accordance with prior studies (3, 17). 
 The mortality component carried more weight than the disability component to 
the DALY calculations for all cancers, which is again in agreement with prior reports 
(3, 13, 17-24). However, for several cancers (e.g., breast, endometrial, prostate, 
melanoma, thyroid and head and neck) more than 25% of the global burden of disease 
was due to years lost due to disability. This strongly highlights the need to consider 
the effects of cancer interventions on disability as well as on mortality, as survival 
rates for many cancer types have been increasing during the last decades in high-
income countries and this trend is likely to continue (25). 
 Cigarette smoking was the predominant risk factor related to DALYs, and was 
responsible for 24.0% of the total cancer burden followed by 4.9% for physical 
inactivity, 1.8% for adiposity, 1.1% for type II diabetes and 0.5% for alcohol. This 
highlights the need to strengthen targeted tobacco control strategies in Europe, which 
are likely to require not only strong government commitment and fiscal measures but 
also the involvement of tobacco control advocates from the civil society and non-
governmental organizations. The Global Burden of Disease study has derived similar 
estimates for the role of each exposure using an alternative modeling approach, which 
relies on published risk estimates of associations and prevalence of exposure. Their 
PAF estimates for total cancer burden were 29% for smoking, 5% for alcohol, 4% for 
adiposity, 3% for physical inactivity and 3% for low fruit and vegetable intake, which 
jointly attributed to 37% of total cancer burden and was similar to estimates observed 
only for cancer mortality (26). Possible explanations for the small differences 
observed in PAF estimates include different relative risks for the studied associations 
and/or different distributions of risk factors in the current study. The observed relative 
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risks in the current study were concordant in the direction of the effect with the 
literature evidence from published meta-analyses with very few exceptions 
(Supplmentary Table 7). However, the participants in the current study are healthy 
volunteers, and include few heavy consumers of alcohol or obese participants, which 
would explain the smaller PAF estimates observed in the current study for alcohol and 
adiposity. The current study findings might not be generalizable to other non-
European populations. 
 We estimated the burden of cancer based on DALYs in five large European 
cohort studies with valid and reliable assessments for cancer incidence, mortality and 
prospective risk factor information. Potential limitations should be also taken into 
account in the interpretation of our results. The calculation of DALYs depends on 
subjective estimates for disability weights for cancer, and our findings should 
therefore be interpreted with caution. However, a prior study that compared DALYs 
lost due to breast cancer in six European countries has shown that the choice of 
disability weights in each country had a small influence, whereas the cross-national 
variation in the epidemiology of breast cancer was responsible for most of the 
observed differences in the burden of breast cancer by country (27). To better account 
for this potential limitation, we used previously published disability weights in the 
Netherlands (12), because they are used in most other burden of disease studies, they 
are differentiated by disease stage and are calculated for a country with comparable 
characteristics for diagnosis and treatment procedures to our study population. When 
we used the lower and the upper estimates of the 95% CIs for the disability weights to 
recalculate DALYs in a sensitivity analysis, we received very similar results. 
 Complete survival data were unavailable from the participating cohorts, 
because they are still ongoing with many participants being alive at the date of 
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administrative censoring. Therefore, we estimated the duration of cancer in the case of 
patients who did not die from their cancer as the minimum of either five years or the 
time interval from cancer diagnosis until the administrative end of the study. The 
burden of disease of some neoplasms, mainly those that led to death after the date of 
administrative censoring and of those that most frequently leave sequelae after their 
potential cure (e.g., prostate, breast, stomach, esophageal, colorectal cancer) are likely 
to have been underestimated using this assumption, and therefore represent a 
minimum estimation of the true burden of disease. However, the 5-year criterion for 
duration of cancer can be considered conservative among survivors and in line with 
the methodology of other burden of disease studies (11, 12, 17). The duration of some 
of the disease phases were also based on expert opinion and were consistently applied 
in other burden of disease studies (11-13, 17). 
 The calculation of DALYs included social values, such as the age-weighting 
function and a discount rate, which may generate another source of uncertainty and 
heterogeneity in our estimates. The age-weighting function gives more relevance to 
deaths occurring in young and middle-aged individuals, and the 3% discount rate 
gives more weight to deaths occurring nearer to the present time (2). Other studies 
have estimated that the joint influence of these two functions on their results was not 
crucial (13, 28), which was verified in a sensitivity analysis performed for the current 
study. 
 In conclusion, our findings along with evidence from a growing literature 
suggest that there are considerable opportunities for improving the overall health 
status of middle-aged and older adults in Europe related to malignancies. Efforts for 
better cancer prevention, early detection and treatment programs should be 
strengthened, but they should also target the improvement of quality of life and 
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palliative care for cancer patients. While smoking remains the predominant risk factor 
for total cancer burden, physical inactivity and adiposity also have important 
additional effects.  
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Table 1. Study and participant characteristics by cohort in the CHANCES consortium of 
middle-aged and older adults* 
Characteristic EPIC-ELDERLY ESTHER NSHDS TROMSO PRIME 
Cohort size, n 39,140 9,220 29,487 9,633 2,719 
Mean follow-up, y 11.6 11.0 12.2 13.4 15.9 
Incident cancer, n 4,218 1,006 3,257 1,527 447 
Death from incident cancer, n 2,016 343 1,064 772 204 
Mean age (SD), y 63.8 (3.5) 62.0 (6.6) 55.6 (4.9) 62.7 (9.5) 54.3 (2.9) 
Male, % 37.9 45.3 50.7 47.5 100 
Mean BMI (SD), kg/m2 27.4 (4.5) 27.7 (4.4) 26.5 (4.6) 26.1 (4.0) 26.2 (3.4) 
Smoking status, %      
Never 49.4 48.6 40.5 33.5 37.4 
Former 27.6 31.9 25.8 34.9 32.4 
Current 21.8 16.7 18.4 31.5 29.0 
Unknown 1.2 2.8 15.3 0.1 1.2 
Current alcohol consumption, 
% 
     
0 g/d 19.6 29.4 6.8 48.6 40.0 
≤10 g/d  44.2 40.1 66.8 43.5 12.1 
>10 g/d 36.0 20.8 9.6 6.8 47.9 
Unknown 0.2 9.7 16.8 1.1 0 
Vigorous physical activity, %      
No 44.2 57.3 60.0 66.2 88.0 
Yes 31.9 42.4 25.5 32.6 12.0 
Unknown 23.9 0.3 14.5 1.2 0 
Diabetes, %      
No 90.6 83.6 NR 95.9 97.6 
Yes 7.0 10.7 NR 3.7 2.4 
Unknown 2.4 5.7 NR 0.4 0 
 21 
 
* Abbreviations: CHANCES, Consortium on Health and Ageing Network of Cohorts in Europe and the 
United States; EPIC-ELDERLY, European Prospective Investigation into Cancer Nutrition-Elderly; 
NSHDS, Northern Sweden Health and Disease Study; PRIME, MORGAM PRIME BELFAST study; 
SD, standard deviation; NR, not reported; g/d, grams/day. 
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Table 2. Number and age-standardized incidence rates (in parentheses) of cancer 
development and death by cohort in the CHANCES consortium of middle-aged and older 
adults* 
Cancer site (ICD10) 
EPIC-ELDERLY ESTHER NSHDS TROMSO PRIME Total 
Cases Deaths Cases Deaths Cases Deaths Cases Deaths Cases Deaths Cases Deaths  
Head & neck (C0-
14, 30-32) 131 (9) 52 (3) 28 (27) 9 (8) 64 (12) 24 (4) 44 (39) 18 (17) 11 (145) 3 (66) 278 (28) 106 (13) 
Esophagus (C15) 52 (6) 43 (5) 11 (10) 9 (8) 18 (59) 15 (57) 27 (23) 23 (18) 7 (8) 6 (6) 115 (13) 96 (11) 
Stomach (C16) 155 (26) 117 (21) 24 (34) 14 (23) 87 (75) 59 (67) 73 (62) 52 (42) 23 (25) 16 (17) 362 (44) 258 (30) 
Small Intestine 
(C17) 11 (2) 8 (1) 1 (1) 0 14 (3) 5 (1) 0 0 2 (2) 2 (2) 28 (3) 15 (2) 
Colorectal (C18-20) 738 (75) 318 (36) 155 (176) 44 (58) 441 (84) 159 (30) 299 (265) 132 (116) 75 (215) 34 (161) 
1,708 
(202) 687 (91) 
Liver (C22) 84 (17) 78 (16) 15 (13) 11 (8) 34 (7) 24 (4) 13 (11) 10 (8) 5 (6) 4 (4) 151 (18) 127 (15) 
Gallbladder (C23-
24) 57 (9) 40 (8) 18 (17) 11 (10) 30 (6) 24 (5) 0 0 3 (3) 3 (3) 108 (11) 78 (8) 
Pancreas (C25) 173 (25) 155 (22) 35 (30) 32 (23) 77 (14) 70 (12) 66 (58) 61 (51) 12 (13) 10 (10) 363 (43) 328 (38) 
Lung (C34) 639 (80) 539 (70) 128 (125) 100 (88) 186 (36) 144 (26) 243 (212) 212 (174) 89 (164) 67 (71) 
1,285 
(146) 1,062 (120) 
Thymus (C37) 4 (0.5) 2 (0.1) 2 (2) 0 2 (0.4) 1 (0.3) 0 0 0 0 8 (0.8) 3 (0.2) 
Heart (C38) 13 (1) 12 (1) 0 0 8 (1) 6 (0.9) 0 0 0 0 21 (2) 18 (1) 
Bone (C40-41) 7 (1) 5 (1) 1 (0.7) 0 3 (0.5) 2 (0.3) 0 0 0 0 11 (1) 7 (0.7) 
Melanoma (C43) 2 (0.7) 1 (0.5) 23 (20) 4 (3) 92 (17) 15 (3) 38 (31) 8 (7) 20 (22) 1 (1) 175 (21) 29 (5) 
Breast (C50) 763 (98) 130 (18) 159 (282) 17 (24) 488 (175) 65 (22) 
148 
(223) 34 (47) 0 0 
1,558 
(254) 246 (40) 
Cervix Uteri (C53) 28 (4) 11 (2) 2 (3) 0 13 (6) 5 (2) 10 (14) 5 (7) 0 0 53 (9) 21 (4) 
Corpus Uteri (C54) 152 (15) 28 (3) 27 (44) 3 (5) 130 (45) 18 (6) 28 (41) 12 (16) 0 0 337 (46) 61 (9) 
Ovaries (C56) 122 (65) 91 (60) 13 (21) 9 (12) 52 (19) 30 (11) 47 (72) 34 (46) 0 0 234 (51) 164 (32) 
Prostate (C61) 678 (162) 161 (57) 198 (379) 12 (19) 
920 
(367) 177 (69) 
287 
(610) 93 (239) 
118 
(195) 17 (18) 
2,201 
(552) 460 (190) 
Kidney (C64) 114 (13) 59 (9) 41 (35) 10 (7) 82 (16) 35 (6) 47 (39) 19 (14) 13 (14) 7 (7) 297 (31) 130 (12) 
Bladder (C67) 167 (21) 64 (11) 34 (56) 14 (23) 
152 
(145) 31 (6) 101 (88) 43 (38) 15 (83) 6 (6) 469 (58) 158 (25) 
Brain & CNS (C70-
72) 92 (11) 82 (9) 19 (16) 16 (11) 105 (19) 47 (9) 47 (38) 15 (12) 9 (10) 9 (10) 272 (28) 169 (15) 
Thyroid (C73) 17 (1) 2 (0.1) 4 (3) 0 21 (4) 5 (0.8) 9 (7) 1 (0.7) 0 0 51 (4) 8 (0.6) 
Hodgkin's (C81) 0 0 4 (5) 1 (1) 2 (0.3) 2 (0.3) 0 0 0 0 6 (0.6) 3 (0.3) 
NHL (C82-85) 3 (0.6) 3 (0.6) 29 (25) 10 (7) 110 (20) 43 (7) 0 0 22 (24) 6 (6) 164 (16) 62 (6) 
Mul. Myeloma 
(C90) 3 (0.4) 2 (0.2) 14 (26) 8 (19) 55 (10) 28 (5) 0 0 7 (74) 4 (67) 79 (9) 42 (5) 
Leukemia (C91-95) 13 (1) 13 (1) 21 (20) 9 (8) 71 (14) 30 (5) 0 0 16 (17) 9 (9) 121 (12) 61 (6) 
Total 
4,218  
(472) 
2,016 
(287) 
1,006 
(1,003) 
343  
(335) 
3,257 
(849) 
1,064 
(307) 
1,527 
(1,317) 
772 
(650) 
447 
(1,021) 
204  
(466) 
10,455  
(1,115) 
4,399 
(519) 
 
*Abbreviations: CHANCES, Consortium on Health and Ageing Network of Cohorts in Europe and the United 
States; EPIC-ELDERLY, European Prospective Investigation into Cancer Nutrition-Elderly; NSHDS, Northern 
Sweden Health and Disease Study; PRIME, MORGAM PRIME BELFAST study; CNS, central nervous system; 
NHL, non Hodgkin's lymphoma. 
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Table 3. Percent of total DALYs* attributable to major cancer risk factors by cancer site in the 
CHANCES consortium of middle-aged and older adults 
Cancer site Smoking 
(current vs. 
never) 
Smoking 
(former vs. 
never) 
Current 
alcohol 
consumption 
(>10 vs. 0 
g/d) 
BMI  
(≥30 vs. <25 
kg/m2) 
BMI  
(25-30 vs. <25 
kg/m2) 
Vigorous 
activity (no vs. 
yes) 
Diabetes (yes 
vs. no) 
Head & 
Neck 
16.0 (13.0, 18.7) 3.4 (1.2, 5.2)    4.9 (0.6, 8.9)  
Esophagus 17.0 (13.1, 20.0) 14.3 (5.4, 
23.1) 
14.1 (6.2, 
21.9) 
    
Stomach 6.9 (2.9, 11.8)       
Colorectal 7.6 (4.8, 10.4) 6.2 (2.4, 10.8)  5.4 (1.8, 8.4)    
Liver 13.0 (9.0, 17.0) 11.0 (2.1, 
19.0) 
   36.0 (20.1, 49.0)  
Gallbladder 0.7 (0.3, 1.1)   10.0 (3.1, 
16.9) 
1.1 (0.2, 1.8)   
Pancreas 10.0 (6.0, 14.0)      2.0 (0.7, 4.0) 
Lung 21.5 (21.1, 21.9) 24.0 (22.1, 
25.0) 
    1.8 (0.3, 2.7) 
Melanoma -12.3 (-18.8, -
3.6) 
    -20.0 (-28.3, -
10.1) 
 
Breast 4.7 (2.6, 6.3) 5.1 (1.5, 9.1) 2.8 (2.4, 3.8)     
Cervix Uteri 2.1 (1.4, 3.0)       
Corpus Uteri -11.7 (-18.4, -
2.9) 
  12.6 (6.7, 
17.9) 
12.2 (4.6, 18.5)   
Prostate 6.5 (3.9, 9.1)   -4.1 (-5.9, -
0.7) 
  -12.1 (-17.3, -
5.5) 
Kidney 16.0 (12.0, 19.1) 13.4 (4.6, 
21.1) 
 9.6 (4.7, 14.5)   2.6 (0.9, 4.3) 
Bladder 18.2 (16.2, 20.2) 20.8 (16.0, 
24.5) 
   3.3 (0.6, 5.4)  
Thyroid      -6.2 (-9.1, -2.9)  
NHL    9.6 (4.0, 14.4)    
Leukemia   -6.5 (-9.6, -
2.2) 
    
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Total 13.5 (12.9, 14.2) 8.2 (6.4, 10.1) 0.5 (0.2, 0.7) 1.8 (0.2, 2.8)  4.9 (0.8, 8.1) 1.1 (0.5, 1.6) 
 
* Cox proportional hazard models were performed to calculate hazard ratios and 95% confidence 
intervals for the association between the afore-mentioned risk factors and cancer incidence and 
mortality by cancer site after pooling together the data from the five participating cohorts 
(Supplementary Table 7). PAFs only for the statistically significant risk factor and cancer site 
incidence or mortality pairs are presented here. Negative values represent protective associations based 
on the initial risk factor modeling, which were then reversed in this table keeping the negative value to 
denote the change in the reference groups. Abbreviations: CHANCES, Consortium on Health and 
Ageing Network of Cohorts in Europe and the United States; BMI, body mass index; NHL, non 
Hodgkin's lymphoma. 
 
 
 
 
 
 
 
 
 
 
Figure legends 
 
Figure 1. Disability-adjusted life years by cancer site in the CHANCES consortium 
of middle-aged and older adults. [Abbreviations: YLD, years of life lost due to disability; 
YLL, years of life lost due to premature mortality; DALY, disability-adjusted life years; CNS, 
central nervous system; NHL, non Hodgkin's lymphoma.] 
 
Figure 2. Disability-adjusted life years by cancer site and sex in the CHANCES 
consortium of middle-aged and older adults. [Abbreviations: YLD, years of life lost due 
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to disability; YLL, years of life lost due to premature mortality; DALY, disability-adjusted 
life years; CNS, central nervous system; NHL, non Hodgkin's lymphoma.]  
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